Vildagliptin Attenuates Hepatic Ischemia/Reperfusion Injury via the TLR4/NF-κB Signaling Pathway

Table 1

Effect of hepatic ischemia/reperfusion (HIR) alone or in combination with intraperitoneal administration of vildagliptin (Vilda) (10 mg/kg for 10 days) on serum alanine transaminase (ALT) and aspartate transaminase (AST) levels in experimental rats. All data were expressed as mean ± SD.

Group	ALT (U/L)	AST (U/L)
Sham	23.52 ± 1.12	47.26 ± 4.6
HIR	86.06 ± 4.71	116.6 ± 8.7
Vilda + HIR	37 ± 5.24	65 ± 4.3

^aSignificant difference from the sham group at . ^bSignificant difference from the HIR group at .